What smart money is saying about Bioxyne
1 fund in our archive has pitched Bioxyne — most recently TAMIM Fund Australia All Cap in June 2025.
Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- TAMIM Fund Australia All CapJune 2025
Bioxyne is a rapidly emerging leader in the medical cannabis manufacturing sector, leveraging its regulatory expertise and advanced production capabilities to target significant international growth and project revenues nearing $100 million within the next few years.
Read the full thesis
Read every full thesis on Bioxyne
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→